Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GFH018 plus toripalimab with concurrent chemoradiotherapy in unresectable locally advanced non-small cell lung cancer
CTR20221875Phase 2Terminated
- Sponsor
- GenFleet Therapeutics
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gfh018, toripalimab in non-small cell lung cancer (NSCLC), sponsored by GenFleet Therapeutics. Started Oct 2022; status: terminated.
02
Drugs
gfh018toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221875.